

Highlights of This Issue 4917

SPECIAL FEATURES

CCR Translations

- 4919 | **Why Is This Effective HSP90 Inhibitor Not Being Developed in HER2+ Breast Cancer?**
Carlos L. Arteaga
See article p. 5132

CCR New Strategies

- 4922 | **New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances**
Keith T. Flaherty and David E. Fisher

Editor's Note

- 4929 | **Introducing CCR Perspectives in Drug Approval**
James L. Abbruzzese

CCR Perspectives in Drug Approval

- 4930 | **The National Institute for Health and Clinical Excellence and Its Role in Assessing the Value of New Cancer Treatments in England and Wales**
Rebecca Trowman, Helen Chung, Carole Longson, Peter Littlejohns, and Peter Clark

Molecular Pathways

- 4936 | **Stem Cell Quiescence**
Ling Li and Ravi Bhatia
- 4942 | **Cancer Stem Cells and Chemosensitivity**
Marcello Maugeri-Saccà, Paolo Vigneri, and Ruggiero De Maria

Review

- 4948 | **Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation**
Per E. Lønning, Ben P. Haynes, Anne H. Straume, Anita Dunbier, Hildegunn Helle, Stian Knappskog, and Mitch Dowsett

Perspective

- 4959 | **To DNA or not to DNA? That Is the Question, When It Comes to Molecular Subtyping for the Clinic!**
Serge J. Smeets, Ulrike Harjes, Wessel N. van Wieringen, Daoud Sie, Ruud H. Brakenhoff, Gerrit A. Meijer, and Bauke Ylstra

HUMAN CANCER BIOLOGY

- 4965 | **Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma**
Takafumi Kubo, Shinichi Toyooka, Kazunori Tsukuda, Masakiyo Sakaguchi, Takuya Fukazawa, Junichi Soh, Hiroaki Asano, Tsuyoshi Ueno, Takayuki Muraoka, Hiromasa Yamamoto, Yasutomo Nasu, Takumi Kishimoto, Harvey I. Pass, Hideki Matsui, Nam-ho Huh, and Shinichiro Miyoshi
- 4975 | **Interleukin-7 Inhibits Tumor-Induced CD27⁻CD28⁻ Suppressor T Cells: Implications for Cancer Immunotherapy**
Yue Zhang, Lukas W. Pfannenstiel, Elzbieta Bolesta, Carolina L. Montes, Xiaoyu Zhang, Andrei I. Chapoval, Ronald B. Gartenhaus, Scott E. Strome, and Brian R. Gastman

CANCER THERAPY: PRECLINICAL

- 4987 | **Adoptive Transfer of Tumor Reactive B Cells Confers Host T-Cell Immunity and Tumor Regression**
Qiao Li, Xiangming Lao, Qin Pan, Ning Ning, Ji Yet, Yingxin Xu, Shengping Li, and Alfred E. Chang

- 4996 **Targeting GPCR-Mediated p70S6K Activity May Improve Head and Neck Cancer Response to Cetuximab**
Neil E. Bholra, Sufi M. Thomas, Maria Freilino, Sonali Joyce, Anirban Sahu, Jessica Maxwell, Athanassios Argiris, Raja Seethala, and Jennifer R. Grandis
- 5005 **Enhanced Metastasis Suppression by Targeting TRAIL Receptor 2 in a Murine Model of Triple-Negative Breast Cancer**
Dmitry Malin, Feng Chen, Carol Schiller, Jennifer Koblinski, and Vincent L. Cryns
- 5016 **Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells**
Marianne E. Marshall, Trista K. Hinz, Scott A. Kono, Katherine R. Singleton, Brady Bichon, Kathryn E. Ware, Lindsay Marek, Barbara A. Frederick, David Raben, and Lynn E. Heasley
- 5026 **Mitoxantrone Inhibits HIF-1 α Expression in a Topoisomerase II-Independent Pathway**
Yng-Miin Toh and Tsai-Kun Li
- 5038 **Enhancement of 5-Fluorouracil-induced *In Vitro* and *In Vivo* Radiosensitization with MEK Inhibition**
Mary Ellen Urick, Eun Joo Chung, William P. Shield, III, Naamit Gerber, Ayla White, Anastasia Sowers, Angela Thetford, Kevin Camphausen, James Mitchell, and Deborah E. Citrin
- 5048 **The Efficacy of IGF-I Receptor Monoclonal Antibody against Human Gastrointestinal Carcinomas is Independent of *k-ras* Mutation Status**
Masanori Ii, Hua Li, Yasushi Adachi, Hiroyuki Yamamoto, Hirokazu Ohashi, Hiroaki Taniguchi, Yoshiaki Arimura, David P. Carbone, Kohzoh Imai, and Yasuhisa Shinomura
- 5060 **Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models**
Yoriko Yamashita-Kashima, Shigeyuki Iijima, Keigo Yorozu, Koh Furugaki, Mitsue Kurasawa, Masateru Ohta, and Kaori Fujimoto-Ouchi
- 5071 **HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors**
Rafal Zielinski, Ilya Lyakhov, Moinuddin Hassan, Monika Kuban, Kimberly Shafer-Weaver, Amir Gandjbakhche, and Jacek Capala

IMAGING, DIAGNOSIS, PROGNOSIS

- 5082 **High *ALK* Receptor Tyrosine Kinase Expression Supersedes *ALK* Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma**
Johannes H. Schulte, Hagen S. Bachmann, Bent Brockmeyer, Katleen DePreter, André Oberthür, Sandra Ackermann, Yvonne Kahlert, Kristian Pajtler, Jessica Theissen, Frank Westermann, Jo Vandesompele, Frank Speleman, Frank Berthold, Angelika Eggert, Benedikt Brors, Barbara Hero, Alexander Schramm, and Matthias Fischer
- 5093 **FDG-PET as a Potential Tool for Selecting Patients with Advanced Non-Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy**
Dok Hyun Yoon, Sora Baek, Chang-Min Choi, Dae Ho Lee, Cheolwon Suh, Jin-Sook Ryu, Dae Hyuk Moon, Jung Shin Lee, and Sang-We Kim


CANCER THERAPY: CLINICAL

- 5101 **Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma**
Marc A. Weniger, Edgar G. Rizzatti, Patricia Pérez-Galán, Delong Liu, Qiuyan Wang, Peter J. Munson, Nalini Raghavachari, Therese White, Megan M. Tweit, Kieron Dunleavy, Yihong Ye, Wyndham H. Wilson, and Adrian Wiestner
- 5113 **Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study**
Steven G. DuBois, Suzanne Shusterman, Ashish M. Ingle, Charlotte H. Ahern, Joel M. Reid, Bing Wu, Sylvain Baruchel, Julia Glade-Bender, Percy Ivy, Holcombe E. Grier, Peter C. Adamson, and Susan M. Blaney
- 5123 **Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1 α in Advanced Solid Tumors**
Shivaani Kummar, Mark Raffeld, Lamin Juwara, Yvonne Horneffer, Agnes Strassberger, Deborah Allen, Seth M. Steinberg, Annamaria Rapisarda, Shawn D. Spencer, William D. Figg, Xiaohong Chen, Ismail Baris Turkbey, Peter Choyke, Anthony J. Murgo, James H. Doroshow, and Giovanni Melillo

5132	<p>HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab</p> <p>Shanu Modi, Alison Stopeck, Hannah Linden, David Solit, Sarat Chandarlapaty, Neal Rosen, Gabriella D'Andrea, Maura Dickler, Mary E. Moynahan, Steven Sugarman, Weining Ma, Sujata Patil, Larry Norton, Alison L. Hannah, and Clifford Hudis</p> <p><i>See commentary p. 4919</i></p>	5170	<p>p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)</p> <p>Jonathan F. Lara, Ann D. Thor, Lynn G. Dressler, Gloria Broadwater, Ira J. Bleiweiss, Susan Edgerton, David Cowan, Lori J. Goldstein, Silvana Martino, James N. Ingle, I. Craig Henderson, Larry Norton, Eric P. Winer, Clifford A. Hudis, Matthew J. Ellis, Donald A. Berry, and Daniel F. Hayes for the Cancer and Leukemia Group B</p>
5140	<p>Comparison of Clinical and Immunological Effects of Intravenous and Intradermal Administration of α-GalactosylCeramide (KRN7000)-Pulsed Dendritic Cells</p> <p>Andrew J. Nicol, Andrea Tazbirkova, and Mie Nieda</p>	5179	<p>Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy</p> <p>Young Joo Lee, Kyong-Ah Yoon, Ji-Youn Han, Heung Tae Kim, Tak Yun, Geon Kook Lee, Hyae Young Kim, and Jin Soo Lee</p>
5152	<p>Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation</p> <p>Danny Rischin, David C. Bibby, Geoff Chong, Gabriel Kremmidiotis, Annabell F. Leske, Clayton A. Matthews, Shirley S. Wong, Mark A. Rosen, and Jayesh Desai</p>	5188	<p>Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials</p> <p>David Olmos, Richard D. Baird, Timothy A. Yap, Christophe Massard, Lorna Pope, Shahneen K. Sandhu, Gerhardt Attard, Juliet Dukes, Dionysis Papadatos-Pastos, Philippa Grainger, Stan B. Kaye, and Johann S. de Bono</p>
PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE			
5161	<p>EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients</p> <p>Siwen Hu-Lieskovan, Daniel Vallbohmer, Wu Zhang, Dongyun Yang, Alexander Pohl, Melissa J. Labonte, Peter P. Grimminger, Arnulf H. Hölscher, Robert Semrau, Dirk Arnold, Kathrin Dellas, Annelies Debucquoy, Karin Haustermans, Jean-Pascal H. Machiels, Christine Sempoux, Claus Rödel, Matej Bracko, Vaneja Velenik, and Heinz-Josef Lenz</p>	5197	<p>Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab–Docetaxel Treatment</p> <p>Ingeborg Tinhofer, Konrad Klinghammer, Wilko Weichert, Maren Knödler, Albrecht Stenzinger, Thomas Gauler, Volker Budach, and Ulrich Keilholz</p>
		5205	<p>Class III β-Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial</p> <p>Adam Christian Vilmar, Eric Santoni-Rugiu, and Jens Benn Sørensen</p>

ABOUT THE COVER

Three-dimensional structure of the trastuzumab/pertuzumab/HER2 ternary complex. Yellow, orange, and magenta are trastuzumab, pertuzumab, and HER2, respectively. Trastuzumab and pertuzumab bind to HER2 without competing with each other. For further details, please see Yamashita-Kashima and coworkers on page 5060 in this issue.



Clinical Cancer Research

17 (15)

Clin Cancer Res 2011;17:4917-5214.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/17/15>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/17/15>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.